CVS Health

Revenue is diversified and largely recurring, supported by insurance premiums, PBM scripts, and pharmacy traffic. However, earnings predictability has been impaired by insurance medical cost volatility and the 2025 goodwill impairment in care delivery.

Q3 2025 saw record revenue of 102.9 billion dollars but a GAAP loss due to a 5.7 billion dollar charge; adjusted EPS guidance was raised, which signals improving operations but not yet steady‑state reliability. Aetna’s star‑rating recovery should aid future MA bonus payments, improving medium‑term visibility.

TTM free cash flow of roughly 6.3 billion dollars remains solid, but cash generation has been choppy relative to earlier years.